Literature DB >> 15931360

Alkaptonuric ochronosis with aortic valve and joint replacements and femoral fracture: a case report and literature review.

Alexander A Fisher1, Michael W Davis.   

Abstract

Alkaptonuria is a rare autosomal recessive disorder of metabolism caused by deficiency of homogentisic acid oxidase and resulting in accumulation of homogentisic acid in collagenous structures. It is characterized by homogentisic aciduria, bluish-black discoloration of connective tissues (ochronosis) and arthropathy of large joints. Less common manifestations include cardiovascular abnormalities, renal, urethral and prostate calculi. Bone fractures are unusual in ochronosis. In this report, we describe a woman, 69 years of age, with a history of dark urine since childhood and progressive pigmentation of the skin, sclera, and auricular cartilages. She had severe arthropathy requiring total joint replacement in both of her knees and right hip. She also had severe aortic stenosis requiring valve replacement, and asymptomatic nephrolithiasis. She presented with a low trauma fracture of the distal femur despite two years of alendroate therapy. We review the etiology, pathogenesis, clinical presentation, diagnosis and treatment of alkaptonuric ochronosis. Early detection is important for prevention and treatment of multiple systems. Nitisinone, a potent inhibitor of 4-hydroxyphenylpyruvate dioxygenase, dramatically reduces production and urinary excretion of homogentisic acid; however, the long-term efficacy and side effects of such therapy are unknown. Identifying the gene for alkaptonuria offers the potential for a new therapeutic approach (replacement therapy with a recombinant enzyme) in the treatment of alkaptonuric ochronosis.

Entities:  

Mesh:

Year:  2004        PMID: 15931360      PMCID: PMC1069096          DOI: 10.3121/cmr.2.4.209

Source DB:  PubMed          Journal:  Clin Med Res        ISSN: 1539-4182


  54 in total

Review 1.  Exogenous ochronosis. An update on clinical features, causative agents and treatment options.

Authors:  C Y Levin; H Maibach
Journal:  Am J Clin Dermatol       Date:  2001       Impact factor: 7.403

Review 2.  Ochronotic arthropathy.

Authors:  Pinar Borman; Hatice Bodur; Deniz Ciliz
Journal:  Rheumatol Int       Date:  2002-03       Impact factor: 2.631

3.  Medical mystery: the answer.

Authors:  A F Nikkels; G E Piérard
Journal:  N Engl J Med       Date:  2001-05-24       Impact factor: 91.245

4.  The coexistence of ochronosis and ankylosing spondylitis.

Authors:  K A Weinberger
Journal:  J Rheumatol       Date:  1991-12       Impact factor: 4.666

5.  Localized argyria with pseudo-ochronosis.

Authors:  Leslie Robinson-Bostom; David Pomerantz; Caroline Wilkel; Russell Mader; Lisa Lerner; Raymond Dufresne; Thomas Flotte
Journal:  J Am Acad Dermatol       Date:  2002-02       Impact factor: 11.527

6.  Black cartilage after therapy with levodopa and methyldopa.

Authors:  A Rausing; U Rosén
Journal:  Arch Pathol Lab Med       Date:  1994-05       Impact factor: 5.534

7.  Ocular ochronosis: A case report and clinical findings.

Authors:  Sevin Söker Cakmak; Remzi Cevik; Ahmet Aksünger; Kaan Unlü; Sedat Ava
Journal:  Acta Ophthalmol Scand       Date:  2002-06

8.  Aortic valve stenosis in alkaptonuric ochronosis.

Authors:  Miha Cercek; Katja Prokselj; Mirta Kozelj
Journal:  J Heart Valve Dis       Date:  2002-05

9.  Exacerbation of the ochronosis of alkaptonuria due to renal insufficiency and improvement after renal transplantation.

Authors:  Wendy J Introne; Chanika Phornphutkul; Isa Bernardini; Kevin McLaughlin; Diana Fitzpatrick; William A Gahl
Journal:  Mol Genet Metab       Date:  2002 Sep-Oct       Impact factor: 4.797

10.  Alkaptonuria in the Dominican Republic: identification of the founder AKU mutation and further evidence of mutation hot spots in the HGO gene.

Authors:  E Goicoechea De Jorge; I Lorda; M E Gallardo; B Pérez; C Peréz De Ferrán; H Mendoza; S Rodríguez De Córdoba
Journal:  J Med Genet       Date:  2002-07       Impact factor: 6.318

View more
  22 in total

Review 1.  The role of nitisinone in tyrosine pathway disorders.

Authors:  Edward Lock; Lakshminarayan R Ranganath; Oliver Timmis
Journal:  Curr Rheumatol Rep       Date:  2014-11       Impact factor: 4.592

2.  A role for interleukins in ochronosis in a chondrocyte in vitro model of alkaptonuria.

Authors:  J B Mistry; D J Jackson; M Bukhari; A M Taylor
Journal:  Clin Rheumatol       Date:  2015-10-16       Impact factor: 2.980

3.  Nine cases of Alkaptonuria in one family in southern Jordan.

Authors:  Mohammed Al-Sbou; Nesrin Mwafi
Journal:  Rheumatol Int       Date:  2010-12-03       Impact factor: 2.631

4.  Arthroscopic diagnosis and treatment of shoulder ochronotic arthropathy - A case report.

Authors:  Prateek Kumar Gupta; Ashis Acharya; Dhananjay Sabat; Amit Mourya
Journal:  J Clin Orthop Trauma       Date:  2017-01-05

5.  [Black knee-ochronotic alterations in alkaptonuria].

Authors:  Elke Maurer; Michael Maurer; Ulrich Stöckle; Ingo Flesch; Atesch Ateschrang; Tobias M Kraus
Journal:  Unfallchirurg       Date:  2019-11       Impact factor: 1.000

6.  Ochronosis with cardiovascular involvement: a case report.

Authors:  Serpil Bal; Yasemin Turan; Hikmet Koçyiğit; Alev Gürgan; Sükran Kurtulmuş; Anil Güvenç; Gonca Deniz
Journal:  Rheumatol Int       Date:  2007-09-25       Impact factor: 2.631

7.  Cerebro-spinal and renal ochronosis: A rare case report.

Authors:  Sunil Kumar Nanda; D R Suresh; A Vamseedhar; K Pratibha; B Arjun
Journal:  Indian J Clin Biochem       Date:  2010-05-27

Review 8.  Alkaptonuria.

Authors:  Jemma B Mistry; Marwan Bukhari; Adam M Taylor
Journal:  Rare Dis       Date:  2013-12-18

9.  Ochronosis as an unusual cause of valvular defect: a case report.

Authors:  Andreas Wilke; Dietmar Steverding
Journal:  J Med Case Rep       Date:  2009-11-27

10.  Ochronosis of hip joint; a case report.

Authors:  Babak Siavashi; Mohammad J Zehtab; Ehsan Pendar
Journal:  Cases J       Date:  2009-12-16
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.